Defining Therapeutic Targets by Using Adenovirus: Blocking NF-κ B Inhibits Both Inflammatory and Destructive Mechanisms in Rheumatoid Synovium but Spares Anti-Inflammatory Mediators

The role of the transcription factor NF-κ B in the pathogenesis of rheumatoid arthritis has long been a subject of controversy. We used an adenoviral technique of blocking NF-κ B through overexpression of the inhibitory subunit Iκ Bα , which has the advantage that it can be used in the diseased tiss...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 96; no. 10; pp. 5668 - 5673
Main Authors Bondeson, Jan, Foxwell, Brian, Brennan, Fionula, Feldmann, Marc
Format Journal Article
LanguageEnglish
Published National Academy of Sciences of the United States of America 11.05.1999
National Acad Sciences
The National Academy of Sciences
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The role of the transcription factor NF-κ B in the pathogenesis of rheumatoid arthritis has long been a subject of controversy. We used an adenoviral technique of blocking NF-κ B through overexpression of the inhibitory subunit Iκ Bα , which has the advantage that it can be used in the diseased tissue itself, with >90% of the synovial macrophages, fibroblasts, and T cells infected. We found that the spontaneous production of tumor necrosis factor α and other pro-inflammatory cytokines is NF-κ B-dependent in rheumatoid synovial tissue, in contrast to the main anti-inflammatory mediators, like IL-10 and -11, and the IL-1 receptor antagonist. Of even more interest, Iκ Bα overexpression inhibited the production of matrix metalloproteinases 1 and 3 while not affecting their tissue inhibitor. Blocking NF-κ B in the rheumatoid joint thus has a very beneficial profile, reducing both the inflammatory response and the tissue destruction. The adenoviral technique described here has widespread applicability, allowing rapid testing of the effects of blocking a potential therapeutic target in either cultures of normal cells or in the diseased tissue itself.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
To whom reprint requests should be addressed. e-mail: m.feldmann@cxwms.ac.uk.
Edited by Anthony Cerami, The Kenneth S. Warren Laboratories, Tarrytown, NY, and approved March 24, 1999
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.96.10.5668